



**Pfizer is seeking proposals for the advancement of therapeutics in the following renal disorders: Polycystic Kidney Disease, Alport Syndrome, Focal Segmental Glomerulosclerosis, IgA Nephropathy**

**Open for Submissions: April 25<sup>th</sup> - June 13<sup>th</sup>, 2022**

**Submissions invited for novel target concepts and therapeutic strategies to slow renal decline. Examples of potential mechanisms for diseases of interest include:**

**Polycystic Kidney Disease  
(Autosomal Dominant and Autosomal Recessive)**

- Reduction of cyst size, growth, & formation
- Cilia formation and function
- Macrophages and tissue resident immunity
- DNA damage response

**Focal Segmental Glomerulosclerosis**

- Targeting glomerular filtration barrier component and cells such as the podocyte
- Slowing glomerulosclerosis
- Parietal epithelial cell modulation

**Alport Syndrome (X-linked Autosomal Dominant)**

- Collagen replacement or re-expression
- Pathways linked to genetic modifiers of renal decline
- Basement membrane and cell matrix dynamics

**IgA Nephropathy**

- Mechanisms to reduce IgA deposition or reduce abnormal IgA glycosylation
- Mesangial cell response

**Technologies, Enabling Infrastructure & Modalities:**

- Small molecules, bio-therapeutics, gene therapy
- Nanoparticle delivery to the kidney and kidney specific compartments and cell types
- RNA elements driving renal specific expression
- AAV Tropism specific to kidney
- Gene expression, replacement, re-expression

**Out of Scope:**

- Cell-based therapies, broad hemodynamic modifiers, complement inhibitors
- Standalone biomarker assays/platforms, medical devices
- Mechanisms specifically targeting non-renal manifestation of disease
- Drug repurposing

**For more information about the submission process and areas of interest go to [pfizercti.com](https://pfizercti.com) or, email [stephen.berasi@pfizer.com](mailto:stephen.berasi@pfizer.com) or [aileen.healy@pfizer.com](mailto:aileen.healy@pfizer.com) or [c.belcher@uniquet.com.au](mailto:c.belcher@uniquet.com.au)**

**Pfizer is seeking proposals for the advancement of therapeutics in the following renal disorders:  
Polycystic Kidney Disease, Alport Syndrome, Focal Segmental Glomerulosclerosis, IgA Nephropathy**

**Open for Submissions: April 25<sup>th</sup> - June 13<sup>th</sup>, 2022**

*Do you have an idea for a collaborative project that would benefit from industry funding and expertise?*

We engage with academia and other public/private entities using a variety of collaborative models:



**RESEARCH  
COLLABORATIONS**



**SEED & VENTURE  
INVESTMENTS**



**JOINT DRUG  
DISCOVERY**

All collaborative models provide access to Pfizer R&D resources and capabilities, helping to advance and translate early innovative concepts to potentially breakthrough medicines for patients.



**INVESTIGATORS ARE  
PAIRED WITH A  
SCIENTIFIC CHAMPION**



**FUNDING IS PROVIDED  
FOR PROJECT-SPECIFIC  
RESEARCH**



**COMPLEMENTARY  
BIOLOGY & DRUG  
DISCOVERY PERFORMED  
AT PFIZER**

**SUBMISSION PROCESS:**

- Develop a 2–3-page non-confidential summary outlining the scientific background and research synopsis

Connect with the Pfizer contact listed below who will review and provide useful guidance on your proposal prior to submission.

**For more information about the submission process and areas of interest go to [pfizercti.com](https://pfizercti.com) or, email [stephen.berasi@pfizer.com](mailto:stephen.berasi@pfizer.com) or [aileen.healy@pfizer.com](mailto:aileen.healy@pfizer.com) or [c.belcher@uniquet.com.au](mailto:c.belcher@uniquet.com.au)**

**Internal submission deadline: email [pfizer@uniquet.com.au](mailto:pfizer@uniquet.com.au) by 6 June 2022  
Pfizer CTI deadline: 13 June 2022**